Precipio Stock (NASDAQ:PRPO)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$14.70

52W Range

$3.90 - $16.89

50D Avg

$11.85

200D Avg

$7.76

Market Cap

$21.77M

Avg Vol (3M)

$11.98K

Beta

1.28

Div Yield

-

PRPO Company Profile


Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

54

IPO Date

Jun 30, 2017

Website

PRPO Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Diagnostic Testing$15.96M$12.40M$4.21M
Service revenue, net$39.17M$26.49M$8.01M

Fiscal year ends in Dec 24 | Currency in USD

PRPO Financial Summary


Dec 24Dec 23Dec 22
Revenue$15.96M$15.20M$9.41M
Operating Income$-4.22M$-7.62M$-12.80M
Net Income$-4.29M$-5.85M$-12.20M
EBITDA$-4.22M$-4.32M$-10.65M
Basic EPS$-2.93$-4.51$-10.73
Diluted EPS$-2.93$-4.51$-10.73

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q1 25May 15, 25 | 5:00 PM
Q4 24Mar 31, 25 | 5:00 PM
Q3 24Nov 18, 24 | 5:00 PM

Peer Comparison


TickerCompany
IMDXInsight Molecular Diagnostics Inc.
PSNLPersonalis, Inc.
XBIOXenetic Biosciences, Inc.
COCPCocrystal Pharma, Inc.
ISPCiSpecimen Inc.
TRIBTrinity Biotech plc